Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Jazz Pharmaceuticals stock | $161.9

Own Jazz Pharmaceuticals stock in just a few minutes.

Fact checked

Jazz Pharmaceuticals plc is a biotechnology business based in the US. Jazz Pharmaceuticals shares (JAZZ) are listed on the NASDAQ and all prices are listed in US Dollars. Jazz Pharmaceuticals employs 1,620 staff and has a trailing 12-month revenue of around USD$2.3 billion.

How to buy shares in Jazz Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Jazz Pharmaceuticals. Find the stock by name or ticker symbol: JAZZ. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Jazz Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$161.9, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Jazz Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Jazz Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Jazz Pharmaceuticals share price

Use our graph to track the performance of JAZZ stocks over time.

Jazz Pharmaceuticals shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$161.9
52-week rangeUSD$86.88 - USD$158.98
50-day moving average USD$147.4862
200-day moving average USD$132.7457
Wall St. target priceUSD$180.89
PE ratio 49.7407
Dividend yield N/A (0%)
Earnings per share (TTM) USD$3.162

Buy Jazz Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Jazz Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Jazz Pharmaceuticals price performance over time

Historical closes compared with the close of $161.9 from 2021-01-11

1 week (2021-01-07) -0.63%
1 month (2020-12-16) 6.69%
3 months (2020-10-16) 7.95%
6 months (2020-07-16) 49.13%
1 year (2020-01-16) 6.80%
2 years (2019-01-16) 26.32%
3 years (2018-01-16) 8.08%
5 years (2016-01-15) 30.14%

Is Jazz Pharmaceuticals under- or over-valued?

Valuing Jazz Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Jazz Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Jazz Pharmaceuticals's P/E ratio

Jazz Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 50x. In other words, Jazz Pharmaceuticals shares trade at around 50x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Jazz Pharmaceuticals's PEG ratio

Jazz Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.9772. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Jazz Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Jazz Pharmaceuticals's EBITDA

Jazz Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1 billion.

The EBITDA is a measure of a Jazz Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Jazz Pharmaceuticals financials

Revenue TTM USD$2.3 billion
Operating margin TTM 29.49%
Gross profit TTM USD$2 billion
Return on assets TTM 7.11%
Return on equity TTM 5.57%
Profit margin 7.86%
Book value $60.75
Market capitalisation USD$8.8 billion

TTM: trailing 12 months

Shorting Jazz Pharmaceuticals shares

There are currently 3.5 million Jazz Pharmaceuticals shares held short by investors – that's known as Jazz Pharmaceuticals's "short interest". This figure is 4.9% down from 3.7 million last month.

There are a few different ways that this level of interest in shorting Jazz Pharmaceuticals shares can be evaluated.

Jazz Pharmaceuticals's "short interest ratio" (SIR)

Jazz Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Jazz Pharmaceuticals shares currently shorted divided by the average quantity of Jazz Pharmaceuticals shares traded daily (recently around 496560.42857143). Jazz Pharmaceuticals's SIR currently stands at 7. In other words for every 100,000 Jazz Pharmaceuticals shares traded daily on the market, roughly 7000 shares are currently held short.

However Jazz Pharmaceuticals's short interest can also be evaluated against the total number of Jazz Pharmaceuticals shares, or, against the total number of tradable Jazz Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Jazz Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Jazz Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.064% of the tradable shares (for every 100,000 tradable Jazz Pharmaceuticals shares, roughly 64 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Jazz Pharmaceuticals.

Find out more about how you can short Jazz Pharmaceuticals stock.

Jazz Pharmaceuticals's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Jazz Pharmaceuticals.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Jazz Pharmaceuticals's total ESG risk score

Total ESG risk: 31.66

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Jazz Pharmaceuticals's overall score of 31.66 (as at 01/01/2019) is nothing to write home about – landing it in it in the 51st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Jazz Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Jazz Pharmaceuticals's environmental score

Environmental score: 4.18/100

Jazz Pharmaceuticals's environmental score of 4.18 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Jazz Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Jazz Pharmaceuticals's social score

Social score: 24.74/100

Jazz Pharmaceuticals's social score of 24.74 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Jazz Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Jazz Pharmaceuticals's governance score

Governance score: 13.74/100

Jazz Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Jazz Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Jazz Pharmaceuticals's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Jazz Pharmaceuticals scored a 1 out of 5 for controversy – the highest score possible, reflecting that Jazz Pharmaceuticals has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Jazz Pharmaceuticals plc was last rated for ESG on: 2019-01-01.

Total ESG score 31.66
Total ESG percentile 51.04
Environmental score 4.18
Environmental score percentile 8
Social score 24.74
Social score percentile 8
Governance score 13.74
Governance score percentile 8
Level of controversy 1

Jazz Pharmaceuticals share dividends

We're not expecting Jazz Pharmaceuticals to pay a dividend over the next 12 months.

Jazz Pharmaceuticals share price volatility

Over the last 12 months, Jazz Pharmaceuticals's shares have ranged in value from as little as $86.88 up to $158.98. A popular way to gauge a stock's volatility is its "beta".

JAZZ.US volatility(beta: 1.06)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jazz Pharmaceuticals's is 1.0583. This would suggest that Jazz Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Jazz Pharmaceuticals overview

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site